Will Insurance or a Government Scheme — Pay for Rituximab?

Both can be correct at the same time. PM-JAY covers treatment packages, and rituximab is covered when it falls within a package that matches your diagnosis code. If the hospital says it falls outside the package, ask them to show you which package your treatment has been coded under and whether an alternative package applies. The PM-JAY trust also has a grievance process — ask the billing team to initiate it if they believe coverage should apply but is being denied.

Manufacturer patient assistance programmes exist for rituximab and are worth asking about at your treating centre. Eligibility is income-based and the process is centre-initiated, not a direct application. Some cancer foundations and NGOs also provide one-time grants or partial subsidies. Ask the hospital's social worker or counsellor — available programmes change and are rarely advertised. We do not publish a current list here because availability shifts; your hospital team will know what is live at the time you ask.

Many policies separate hospitalisation costs from drug costs and apply a lower sub-limit — or an outright exclusion — to biologic medicines. This is a known gap in a large number of Indian private policies. For the current treatment, put your appeal in writing and ask the insurer to cite the exact policy clause that excludes it. Some initial rejections are overturned on formal appeal. When you next renew, look specifically for plans that state biologic or targeted therapy coverage without a separate sub-limit.

Ask your oncologist to apply for a medical exemption or special consideration through the Aarogyasri Trust. This mechanism exists for treatments that are clinically indicated but not on the standard approved list. The application needs a written clinical justification from the treating specialist. It does not always succeed, but it is the correct next step before concluding that the scheme cannot help. The Trust's medical committee reviews such applications on their merits.

Yes, in some circumstances. CGHS covers treatment at empanelled private hospitals for beneficiaries who hold a referral from a CGHS-authorised doctor. Rituximab costs are reimbursed at CGHS-approved rates, which may be lower than the private hospital's actual charge — the difference would be your liability. Ask your CGHS wellness centre for the current approved rate before your first cycle begins, so you know what out-of-pocket difference to expect.

Possibly. CGHS allows retrospective reimbursement in some circumstances, particularly when treatment was urgent. PM-JAY reimbursement for treatment already received is harder to obtain because pre-authorisation is a scheme condition. Private insurance reimbursement depends on your policy terms and the documented reason why pre-authorisation was not sought beforehand. Gather every bill, prescription, lab report and discharge summary and submit a written claim with a clear explanation — the outcome turns on the scheme's rules and the reason for the delay.